IL225879A0 - Single-therapeutic formulations of selective, lipophilic and long-acting beta agonists and methods for cosmetic treatment of contour bumps and obesity - Google Patents

Single-therapeutic formulations of selective, lipophilic and long-acting beta agonists and methods for cosmetic treatment of contour bumps and obesity

Info

Publication number
IL225879A0
IL225879A0 IL225879A IL22587913A IL225879A0 IL 225879 A0 IL225879 A0 IL 225879A0 IL 225879 A IL225879 A IL 225879A IL 22587913 A IL22587913 A IL 22587913A IL 225879 A0 IL225879 A0 IL 225879A0
Authority
IL
Israel
Prior art keywords
adiposity
lipophilic
selective
methods
long
Prior art date
Application number
IL225879A
Other languages
English (en)
Hebrew (he)
Original Assignee
Lithera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lithera Inc filed Critical Lithera Inc
Publication of IL225879A0 publication Critical patent/IL225879A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q90/00—Cosmetics or similar toiletry preparations for specific uses not provided for in other groups of this subclass
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
IL225879A 2010-11-24 2013-04-22 Single-therapeutic formulations of selective, lipophilic and long-acting beta agonists and methods for cosmetic treatment of contour bumps and obesity IL225879A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41709810P 2010-11-24 2010-11-24
PCT/US2011/061973 WO2012074856A2 (en) 2010-11-24 2011-11-22 Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging

Publications (1)

Publication Number Publication Date
IL225879A0 true IL225879A0 (en) 2013-06-27

Family

ID=45475499

Family Applications (1)

Application Number Title Priority Date Filing Date
IL225879A IL225879A0 (en) 2010-11-24 2013-04-22 Single-therapeutic formulations of selective, lipophilic and long-acting beta agonists and methods for cosmetic treatment of contour bumps and obesity

Country Status (17)

Country Link
US (2) US9597531B2 (OSRAM)
EP (1) EP2646012A4 (OSRAM)
JP (1) JP2013543897A (OSRAM)
KR (1) KR20140025312A (OSRAM)
CN (2) CN105832681A (OSRAM)
AU (1) AU2011336869B2 (OSRAM)
BR (1) BR112013012994A2 (OSRAM)
CA (1) CA2815374A1 (OSRAM)
EA (1) EA201270784A1 (OSRAM)
GB (1) GB2485885B (OSRAM)
GE (1) GEP201606551B (OSRAM)
IL (1) IL225879A0 (OSRAM)
MX (1) MX2013005873A (OSRAM)
SG (1) SG190878A1 (OSRAM)
TW (1) TW201231042A (OSRAM)
UA (1) UA111822C2 (OSRAM)
WO (1) WO2012074856A2 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006270165B2 (en) 2005-07-14 2010-03-11 Neothetics, Inc. Sustained release enhanced lipolytic formulation for regional adipose tissue treatment
ES2398480T3 (es) * 2006-10-17 2013-03-19 Lithera, Inc. Procedimientos, composiciones, y formulaciones para el tratamiento de la enfermedad ocular tiroidea
US9132084B2 (en) * 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
JP2013517294A (ja) * 2010-01-15 2013-05-16 リセラ，インク． 凍結乾燥ケーキ製剤

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3898330A (en) 1973-08-01 1975-08-05 Squibb & Sons Inc Corticosteroid phosphate salts/neomycin sulfate ophthalmic
US4525359A (en) 1982-12-10 1985-06-25 Greenway Frank L Iii Treatment for selective weight control
NZ212204A (en) 1984-06-04 1988-07-28 Merck & Co Inc Growth-promoting compositions containing hydroxylic compounds
GB8426672D0 (en) 1984-10-22 1984-11-28 Erba Farmitalia Pharmaceutical compositions
JPH0696521B2 (ja) 1986-01-31 1994-11-30 千寿製薬株式会社 眼局所投与用眼圧降下剤
FR2602423B1 (fr) 1986-08-08 1989-05-05 Ethypharm Sa Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede
US5270305A (en) 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
CA2030174C (en) 1990-01-10 1996-12-24 Anthony H. Cincotta Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hypoglycemia in vertebrates
US5126147A (en) 1990-02-08 1992-06-30 Biosearch, Inc. Sustained release dosage form
US5919827A (en) 1990-07-11 1999-07-06 Sepracor Inc. Method for treating asthma using optically pure R(-) salmeterol
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
WO1993011773A1 (en) 1991-12-18 1993-06-24 Aktiebolaget Astra New combination of formoterol and budesonide
US5314916A (en) 1993-04-19 1994-05-24 Alcon Laboratories, Inc. B2 adrenegic agonists and use thereof in the treatment of glaucoma
US6316443B1 (en) 1994-08-04 2001-11-13 Merck & Co., Inc. Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a β-adrenergic antagonist
GB9512854D0 (en) 1995-06-23 1995-08-23 Wellcome Found Novel formulation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
AU4582797A (en) 1996-09-13 1998-04-02 Regents Of The University Of California, The Methods for treatment of retinal diseases
AU733716B2 (en) 1996-09-19 2001-05-24 Regents Of The University Of Michigan, The Polymers containing polysaccharides such as alginates or modified alginates
SE9700135D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
TW469832U (en) 1997-03-14 2001-12-21 Astra Ab Inhalation device
EP0998300A1 (en) 1997-03-18 2000-05-10 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
US6656508B2 (en) 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
JP2001527545A (ja) 1997-04-30 2001-12-25 ブリッジ ファーマ，インコーポレーテッド ユートマーを使用する組成物および方法
US20010044584A1 (en) 1997-08-28 2001-11-22 Kensey Kenneth R. In vivo delivery methods and compositions
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
JPH11106334A (ja) * 1997-09-30 1999-04-20 Saitama Daiichi Seiyaku Kk 尿失禁治療剤
US20030095925A1 (en) 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
US20040152664A1 (en) 1998-09-02 2004-08-05 Allergan, Inc. Prednisolone compositions
US6384259B1 (en) 1998-11-16 2002-05-07 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and dosage form
AU7127600A (en) 1999-09-17 2001-04-17 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
GB9924992D0 (en) 1999-10-21 1999-12-22 Glaxo Group Ltd Pharmaceutical aerosol formulations
WO2001041806A1 (en) 1999-12-07 2001-06-14 Rohto Pharmaceutical Co., Ltd. Ophthalmic compositions
US20040208910A1 (en) 2000-04-26 2004-10-21 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of adrenergic agents
GB0012260D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
AUPQ797700A0 (en) 2000-06-06 2000-06-29 Austin Research Institute, The Vaccine
US6936426B2 (en) 2000-10-06 2005-08-30 Harbor-Ucla Research And Education Institute Detection of antibody mediated inflammatory auto-immune disorders
FI20002216A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
FI20002215A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
EP1330636A1 (en) 2000-11-03 2003-07-30 Histotech Aps A device and a method for sectioning of tissue blocks
ES2260321T3 (es) 2000-12-07 2006-11-01 Universiteit Utrecht Holding B.V. Composicion para el tratamiento de transtornos inflamatorios.
WO2002060410A2 (en) 2001-01-30 2002-08-08 The Regents Of The University Of Michigan Methods for sustained release local delivery of drugs for ablation of unwanted tissue
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
PL366937A1 (en) 2001-04-30 2005-02-07 Glaxo Group Limited Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
GB0124523D0 (en) 2001-10-12 2001-12-05 Glaxo Group Ltd Pharmaceutical combination
EP1438019A1 (en) 2001-10-24 2004-07-21 PARI GmbH Spezialisten für effektive Inhalation Kit for the preparation of a pharmaceutical composition
US6625078B2 (en) 2002-02-11 2003-09-23 United Memories, Inc. Look-ahead refresh for an integrated circuit memory
US8541399B2 (en) 2002-02-19 2013-09-24 Resolution Chemicals Limited Solvent-based sterilisation of pharmaceuticals
US20050009798A1 (en) 2002-02-20 2005-01-13 Sepracor Inc. Carbonate and carbamate modified forms of glucocorticoids in combination with B2 adrenergic agonists
US6643212B1 (en) 2002-04-18 2003-11-04 United Memories, Inc. Simultaneous function dynamic random access memory device technique
WO2004028545A1 (en) 2002-09-25 2004-04-08 Astrazeneca Ab A COMBINATION OF A LONG-ACTING β2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
EP1556018A1 (en) 2002-09-30 2005-07-27 Acusphere, Inc. Sustained release porous microparticles for inhalation
US20040208833A1 (en) 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
EP1613266A4 (en) 2003-04-15 2009-05-06 Theraquest Biosciences Llc METHOD FOR TREATING PAIN AND COMPOSITIONS FOR USE THEREOF
US9808471B2 (en) 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
WO2004103057A2 (en) * 2003-05-15 2004-12-02 The University Of Georgia Research Foundation, Inc. Compositions and methods for inducing adipose tissue cell death
AU2004241746A1 (en) 2003-05-22 2004-12-02 Nycomed Gmbh Salmeterol and ciclesonide combination
SE0302029D0 (sv) 2003-07-07 2003-07-07 Astrazeneca Ab Novel process
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
GB2403655A (en) 2003-07-11 2005-01-12 Cipla Ltd Combined pharmaceutical product comprising a beta-2 adrenoreceptor agonist & an antihistamine for treatment of respiratory diseases such as asthma
WO2005009375A2 (en) 2003-07-22 2005-02-03 Baxter International Inc. Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof
EP1667659A1 (en) 2003-09-30 2006-06-14 Acusphere, Inc. Injectable, oral, or topical sustained release pharmaceutical formulations
US20050075900A1 (en) 2003-10-02 2005-04-07 Arguimbau Vincent C. Method and apparatus for bulk food marking and tracking with supplier rating system
DE10347994A1 (de) 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
DK1682537T3 (da) 2003-11-05 2012-07-09 Sarcode Bioscience Inc Modulatorer af celleadhæsion
EP1684593A4 (en) * 2003-11-20 2010-02-10 Alteragon Pty Ltd METHOD FOR REDUCING FAT DEPOSITS AND BODY WEIGHT IN MAMMALS AND BIRDS
KR100573828B1 (ko) 2003-12-29 2006-04-26 주식회사 하이닉스반도체 셀데이터의 손실을 방지하기 위한 반도체 메모리 소자
US20080270175A1 (en) 2003-12-31 2008-10-30 Klinger Advanced Aesthetics, Inc. Systems and methods using a dynamic expert system to provide patients with aesthetic improvement procedures
US20050212152A1 (en) 2004-03-23 2005-09-29 Reens Daniel J System and method for humidifying homes and commercial sites
US7754230B2 (en) 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat
EP1778638A1 (en) 2004-07-21 2007-05-02 Theravance, Inc. Diaryl ether beta2 adrenergic receptor agonists
AU2004325203A1 (en) 2004-11-24 2006-06-01 Seo Hong Yoo Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
CN101119733A (zh) 2005-02-18 2008-02-06 参天制药株式会社 减轻或避免甾族化合物副作用的方法
WO2006108176A2 (en) 2005-04-08 2006-10-12 The Regents Of The University Of California Wound healing composition
US7931909B2 (en) 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
CN1706501A (zh) 2005-05-27 2005-12-14 沈阳药科大学 亲脂性药物环糊精包合物的制备方法
AU2006270165B2 (en) 2005-07-14 2010-03-11 Neothetics, Inc. Sustained release enhanced lipolytic formulation for regional adipose tissue treatment
CN101252842A (zh) * 2005-07-14 2008-08-27 利波西拉公司 用于局部脂肪组织治疗的持续释放的增强性脂肪分解性制剂
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
FR2893845B1 (fr) 2005-11-30 2010-10-29 Galderma Sa Composition sous forme de spray comprenant un corticoide et une phase huileuse
JP2009519972A (ja) 2005-12-15 2009-05-21 アキュスフィア， インコーポレイテッド 粒子ベースの経肺投与または経鼻投与用製薬の製造方法
US20070178051A1 (en) 2006-01-27 2007-08-02 Elan Pharma International, Ltd. Sterilized nanoparticulate glucocorticosteroid formulations
MX2008012794A (es) 2006-04-03 2008-10-15 Teva Pharma Microparticulas de farmacos.
DE102007026979A1 (de) 2006-10-06 2008-04-10 Friedrich Siller Inhalationsvorrichtung
CN101626759B (zh) * 2006-10-17 2014-08-06 利特拉公司 用于治疗甲状腺眼病的组合物和制剂
ES2398480T3 (es) 2006-10-17 2013-03-19 Lithera, Inc. Procedimientos, composiciones, y formulaciones para el tratamiento de la enfermedad ocular tiroidea
WO2008066775A2 (en) 2006-11-22 2008-06-05 Duncan Diane I Compositions and methods to reduce fat and retract skin
EP2142207A4 (en) 2007-04-04 2013-01-16 Theratechnologies Inc PHARMACEUTICAL FORMULATIONS OF GHRH MOLECULES
WO2008129308A2 (en) * 2007-04-24 2008-10-30 Acacia Pharma Limited Drug combination and its use in the treatment of muscle loss
US20090208492A1 (en) 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
BRPI0814716A2 (pt) 2007-06-22 2015-02-24 Dompe Spa Comprimidos efervescentes para uso em inalação
US9050368B2 (en) 2007-11-13 2015-06-09 Meritage Pharma, Inc. Corticosteroid compositions
AU2008331928B2 (en) 2007-12-03 2012-08-16 Bridge Pharma, Inc. Use of RR/SR-ractopamine
US9132084B2 (en) * 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
JP2013517294A (ja) * 2010-01-15 2013-05-16 リセラ，インク． 凍結乾燥ケーキ製剤

Also Published As

Publication number Publication date
AU2011336869B2 (en) 2016-09-15
BR112013012994A2 (pt) 2016-09-13
KR20140025312A (ko) 2014-03-04
GEP201606551B (en) 2016-10-10
EP2646012A4 (en) 2014-12-10
EP2646012A2 (en) 2013-10-09
GB2485885A (en) 2012-05-30
AU2011336869A1 (en) 2013-05-09
MX2013005873A (es) 2013-08-07
US20120178819A1 (en) 2012-07-12
WO2012074856A3 (en) 2013-04-04
US20170135923A1 (en) 2017-05-18
SG190878A1 (en) 2013-07-31
EA201270784A1 (ru) 2013-04-30
TW201231042A (en) 2012-08-01
GB2485885B (en) 2015-06-17
UA111822C2 (uk) 2016-06-24
GB201120090D0 (en) 2012-01-04
CN105832681A (zh) 2016-08-10
JP2013543897A (ja) 2013-12-09
WO2012074856A2 (en) 2012-06-07
US9597531B2 (en) 2017-03-21
CA2815374A1 (en) 2012-06-07
CN103269693A (zh) 2013-08-28

Similar Documents

Publication Publication Date Title
PL2701684T3 (pl) Ulepszone preparaty pozajelitowe lipofilowych środków farmaceutycznych oraz sposoby ich wytwarzania i stosowania
IL221160A (en) 4,2,1-triazine-3-amine derivatives, a process for their preparation and use for drug preparation
ZA201209632B (en) Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof
IL231386A0 (en) Pyrazoloquinolinone derivatives, their preparation and medical use
ZA201300100B (en) Indolizine derivatives,process for the preparation thereof and therapeutic use thereof
IL232906A (en) Pyrazolopyridine derivatives, a process for their preparation and medical use
SG11201400769PA (en) Quinolyl-containing Hydroxamic Acid Compound and Preparation Method Thereof, and Pharmaceutical Composition Containing This Compound and Use Thereof
GB0903158D0 (en) Cosmetic or pharmaceutical preparation for the skin
EP2404591A4 (en) COSMETIC PREPARATION, METHOD FOR THE PRODUCTION THEREOF, COMPOSITION FOR COSMETICS PREPARATIONS, METHOD FOR THE PRODUCTION THEREOF, COSMETIC PREPARATION WITH THE COMPOSITION FOR COSMETICS PREPARATIONS AND METHOD FOR THE PRODUCTION THEREOF, AND CLEANERS FOR INDUSTRIAL USE
ZA201400188B (en) Substituted cinnamamide derivative, preparation method and use thereof
IL232970A0 (en) Oral spray compounds
IL220738A0 (en) Arylsulfonamide pyridine-pyridinone derivatives, preparation of same, and therapeutic use thereof
EP2924042A4 (en) BIS-BETA-CARBOLINE COMPOUND AND METHOD OF MANUFACTURING, PHARMACEUTICAL COMPOSITION AND USE THEREOF
SG10201405125YA (en) Composition for hair cosmetic preparation and production method of the same
GB2479246B (en) Make-up composition for the skin, its process of preparation and a make-up method
IL225879A0 (en) Single-therapeutic formulations of selective, lipophilic and long-acting beta agonists and methods for cosmetic treatment of contour bumps and obesity
IL225755A0 (en) Amido-6 derivatives of epoxymorphinans-a5, 4 for the treatment of pain
EP2701689A4 (en) PHARMACEUTICAL COMPOSITIONS OF RALTEEGRAVIR, METHODS OF PREPARATION AND USE THEREOF
PL2662382T3 (pl) Metoda przygotowywania pochodnych sterolu oraz zawierających je składów farmaceutycznych, a także stosowania ich w leczeniu licznych glejaków
EP2610257A4 (en) DIIMIDED DERIVATIVE OF BERBAMINE, MANUFACTURING METHOD AND ITS USE
GB201120091D0 (en) Lipophilic glucocorticosteriod monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging
HK1189819A (en) Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging
EP2565180A4 (en) ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE PRODUCTION METHOD AND PHARMACEUTICAL COMPOSITION THEREWITH
IL226388A0 (en) New indolizine derivatives, their preparation and medical use
ZA201303663B (en) Apparatus for conducting oral care experiments and method of forming and using the same